Costs and Benefits of Including Inactivated in Addition to Oral Poliovirus Vaccine in Outbreak Response After Cessation of Oral Poliovirus Vaccine Use

Background: After stopping serotype 2–containing oral poliovirus vaccine use, serotype 2 poliovirus outbreaks may still occur and require outbreak response supplemental immunization activities (oSIAs). Current oSIA plans include the use of both serotype 2 monovalent oral poliovirus vaccine (mOPV2) and inactivated poliovirus vaccine (IPV). Methods: We used an existing model to compare the effectiveness of mOPV2 oSIAs with or without IPV in response to a hypothetical postcessation serotype 2 outbreak in northwest Nigeria. We considered strategies that co-administer IPV with mOPV2, use IPV only for older age groups, or use only IPV during at least one oSIA. We considered the cost and supply implications and estimated from a societal perspective the incremental cost-effectiveness and incremental net benefits of adding IPV to oSIAs in the context of this hypothetical outbreak in 2017. Results: Adding IPV to the first or second oSIA resulted in a 4% to 6% reduction in expected polio cases compared to exclusive mOPV2 oSIAs. We found the greatest benefit of IPV use if added preemptively as a ring around the initial oSIA target population, and negligible benefit if added to later oSIAs or older age groups. We saw an increase in expected polio cases if IPV replaced mOPV2 during an oSIA. None of the oSIA strategies that included IPV for this outbreak represented a cost-effective or net beneficial intervention compared to reliance on mOPV2 only. Conclusions: While adding IPV to oSIAs results in marginal improvements in performance, the poor cost-effectiveness and current limited IPV supply make it economically unattractive for high-risk settings in which IPV does not significantly affect transmission.

[1]  Poliovirus vaccine inactivated , 2018, Reactions Weekly.

[2]  K. Thompson,et al.  Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use , 2016, BMC Infectious Diseases.

[3]  K. Thompson,et al.  Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation , 2016, BMC Infectious Diseases.

[4]  M. Pallansch,et al.  Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame , 2016, BMC Infectious Diseases.

[5]  F. Mahoney,et al.  Mass immunization with inactivated polio vaccine in conflict zones – Experience from Borno and Yobe States, North-Eastern Nigeria , 2016, Journal of public health policy.

[6]  R. Price,et al.  Improving the radical cure of vivax malaria (IMPROV): a study protocol for a multicentre randomised, placebo-controlled comparison of short and long course primaquine regimens , 2015, BMC Infectious Diseases.

[7]  M. Pallansch,et al.  Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: A randomized controlled trial. , 2015, Vaccine.

[8]  N. Molodecky,et al.  Needle-free jet injector intradermal delivery of fractional dose inactivated poliovirus vaccine: Association between injection quality and immunogenicity. , 2015, Vaccine.

[9]  M. Pallansch,et al.  An economic analysis of poliovirus risk management policy options for 2013–2052 , 2015, BMC Infectious Diseases.

[10]  K. Thompson,et al.  Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs , 2015, BMC Infectious Diseases.

[11]  M. Pallansch,et al.  Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs , 2015, BMC Infectious Diseases.

[12]  K. Thompson,et al.  The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission , 2015, BMC Infectious Diseases.

[13]  K. Thompson,et al.  Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes , 2015, BMC Infectious Diseases.

[14]  M. Pallansch,et al.  Combinations of Quality and Frequency of Immunization Activities to Stop and Prevent Poliovirus Transmission in the High-Risk Area of Northwest Nigeria , 2015, PloS one.

[15]  M. Pallansch,et al.  Modeling options to manage type 1 wild poliovirus imported into Israel in 2013. , 2015, The Journal of infectious diseases.

[16]  M. Pallansch,et al.  Modeling undetected live poliovirus circulation after apparent interruption of transmission: implications for surveillance and vaccination , 2015, BMC Infectious Diseases.

[17]  R. Sutter,et al.  Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba. , 2015, Vaccine.

[18]  Philip A. Eckhoff,et al.  Quantifying the Impact of Expanded Age Group Campaigns for Polio Eradication , 2014, PloS one.

[19]  G. Armstrong,et al.  Possible Eradication of Wild Poliovirus Type 3 — Worldwide, 2012 , 2014, MMWR. Morbidity and mortality weekly report.

[20]  Hiromasa Okayasu,et al.  Affordable inactivated poliovirus vaccine: strategies and progress. , 2014, The Journal of infectious diseases.

[21]  R. Sutter,et al.  Vaccine-derived polioviruses. , 2014, The Journal of infectious diseases.

[22]  K. Thompson,et al.  Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation. , 2014, The Journal of infectious diseases.

[23]  R. Sutter,et al.  Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. , 2014, The Journal of infectious diseases.

[24]  K. Thompson,et al.  Modeling strategies to increase population immunity and prevent poliovirus transmission in 2 high-risk areas in northern India. , 2014, The Journal of infectious diseases.

[25]  K. Thompson,et al.  Modeling the dynamics of oral poliovirus vaccine cessation. , 2014, The Journal of infectious diseases.

[26]  G. Kang,et al.  Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial , 2014, The Lancet.

[27]  N. Grassly,et al.  The role of older children and adults in wild poliovirus transmission , 2014, Proceedings of the National Academy of Sciences.

[28]  M. Pallansch,et al.  The potential impact of expanding target age groups for polio immunization campaigns , 2014, BMC Infectious Diseases.

[29]  K. Thompson,et al.  National choices related to inactivated poliovirus vaccine, innovation and the endgame of global polio eradication , 2014, Expert review of vaccines.

[30]  Modeling strategies to increase population immunity and prevent poliovirus transmission in the high-risk area of northwest Nigeria. , 2014, The Journal of infectious diseases.

[31]  M. Pallansch,et al.  Poliovirus vaccination options for achieving eradication and securing the endgame. , 2013, Current opinion in virology.

[32]  M. Pallansch,et al.  Characterizing Poliovirus Transmission and Evolution: Insights from Modeling Experiences with Wild and Vaccine‐Related Polioviruses , 2013, Risk analysis : an official publication of the Society for Risk Analysis.

[33]  M. Pallansch,et al.  Oral Poliovirus Vaccine Evolution and Insights Relevant to Modeling the Risks of Circulating Vaccine‐Derived Polioviruses (cVDPVs) , 2013, Risk analysis : an official publication of the Society for Risk Analysis.

[34]  M. Pallansch,et al.  Expert Review on Poliovirus Immunity and Transmission , 2013, Risk analysis : an official publication of the Society for Risk Analysis.

[35]  M. Pallansch,et al.  Review and Assessment of Poliovirus Immunity and Transmission: Synthesis of Knowledge Gaps and Identification of Research Needs , 2013, Risk analysis : an official publication of the Society for Risk Analysis.

[36]  R. D. Tebbens,et al.  Modeling Population Immunity to Support Efforts to End the Transmission of Live Polioviruses , 2013, Risk analysis : an official publication of the Society for Risk Analysis.

[37]  M. Pallansch,et al.  Preeradication Vaccine Policy Options for Poliovirus Infection and Disease Control , 2013, Risk analysis : an official publication of the Society for Risk Analysis.

[38]  David Moher,et al.  Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[39]  R. Sutter,et al.  Priming after a fractional dose of inactivated poliovirus vaccine. , 2013, The New England journal of medicine.

[40]  S. Plotkin,et al.  27 – Poliovirus vaccine—inactivated , 2013 .

[41]  R. Sutter,et al.  28 – Poliovirus vaccine—live , 2013 .

[42]  N. Grassly,et al.  Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge , 2012, PLoS pathogens.

[43]  M. Pate,et al.  Outbreak of Type 2 Vaccine-Derived Poliovirus in Nigeria: Emergence and Widespread Circulation in an Underimmunized Population , 2011, The Journal of infectious diseases.

[44]  M. Pallansch,et al.  Economic analysis of the global polio eradication initiative. , 2010, Vaccine.

[45]  N. Nathanson,et al.  From Emergence to Eradication: The Epidemiology of Poliomyelitis Deconstructed , 2010, American journal of epidemiology.

[46]  Kimberly M Thompson,et al.  Uncertainty and Sensitivity Analyses of a Decision Analytic Model for Posteradication Polio Risk Management , 2008, Risk analysis : an official publication of the Society for Risk Analysis.

[47]  Kimberly M Thompson,et al.  The risks, costs, and benefits of possible future global policies for managing polioviruses. , 2008, American journal of public health.

[48]  R. Sutter,et al.  Poliovirus vaccine-live , 2008 .

[49]  Kimberly M Thompson,et al.  Risks of Paralytic Disease Due to Wild or Vaccine‐Derived Poliovirus After Eradication , 2006, Risk analysis : an official publication of the Society for Risk Analysis.

[50]  Kimberly M Thompson,et al.  A dynamic model of poliomyelitis outbreaks: learning from the past to help inform the future. , 2005, American journal of epidemiology.

[51]  M. Pallansch,et al.  Vaccine policy changes and epidemiology of poliomyelitis in the United States. , 2004, JAMA.

[52]  T. Edejer,et al.  Generalized cost-effectiveness analysis for national-level priority-setting in the health sector , 2003, Cost effectiveness and resource allocation : C/E.

[53]  M. Pallansch,et al.  Outbreak of Poliomyelitis in Hispaniola Associated with Circulating Type 1 Vaccine-Derived Poliovirus , 2002, Science.

[54]  M. Pallansch,et al.  Seroprevalence of antibody against poliovirus in inner-city preschool children. Implications for vaccination policy in the United States. , 1996, JAMA.

[55]  Alan D. Lopez,et al.  The global burden of disease: a comprehensive assessment of mortality and disability from diseases injuries and risk factors in 1990 and projected to 2020. , 1996 .

[56]  J. Andrus,et al.  Lessons from Cuba: mass campaign administration of trivalent oral poliovirus vaccine and seroprevalence of poliovirus neutralizing antibodies. , 1994, Bulletin of the World Health Organization.

[57]  P. Wright,et al.  Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. , 1991, Reviews of infectious diseases.

[58]  A. Blanc Demographic and health surveys , 1991 .

[59]  T. John,et al.  Efficacy of inactivated poliovirus vaccine in India. , 1983, Bulletin of the World Health Organization.

[60]  F. Maccallum Hypogammaglobulinaemia in the United Kingdom. VII. The role of humoral antibodies in protection against and recovery from bacterial and virus infections in hypogammaglobulinaemia. , 1971, Special report series (Medical Research Council (Great Britain)).

[61]  J. Paul,et al.  The incubation period in human poliomyelitis and its implications. , 1947, Journal of the American Medical Association.

[62]  Census Figures.—(I.) , 1910 .